Novel targets for prostate cancer chemoprevention

Endocrine-Related Cancer

Volumn 17, Issue 3, 2010, Pages

  Sarkar, Fazlul H ^a   Li, Yiwei ^a   Wang, Zhiwei ^a   Kong, Dejuan ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN RECEPTOR; DUTASTERIDE; FINASTERIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE; LYCOPENE; NOTCH RECEPTOR; PROTEIN KINASE B; SELENIUM; SONIC HEDGEHOG PROTEIN; STEROID 5ALPHA REDUCTASE INHIBITOR; VITAMIN D; WNT PROTEIN;

CANCER GROWTH; CANCER PREVENTION; CARCINOGENESIS; DRUG MECHANISM; METASTASIS; PROSTATE CANCER; REVIEW; TEA;

ANIMALS; ANTICARCINOGENIC AGENTS; HUMANS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 77956381416     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0074     Document Type: Review

References (172)

1. Adhami VM, Siddiqui IA, Ahmad N, Gupta S & Mukhtar H 2004 Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Research 64 8715-8722. (Pubitemid 39552088)
2. Adhami VM, Siddiqui IA, Sarfaraz S, Khwaja SI, Hafeez BB, Ahmad N & Mukhtar H 2009 Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clinical Cancer Research 15 1947-1953.
3. Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hamalainen E, Hasegawa T & Okada H 1991 Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. American Journal of Clinical Nutrition 54 1093-1100. (Pubitemid 21917676)
4. Adlercreutz H, Markkanen H & Watanabe S 1993 Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342 1209-1210. (Pubitemid 23331713)
5. Ahmad N, Gupta S & Mukhtar H 2000 Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Archives of Biochemistry and Biophysics 376 338-346. (Pubitemid 30210882)
6. Ahmad A, Kong D, Sarkar SH, Wang Z, Banerjee S & Sarkar FH 2009 Inactivation of uPA and its receptor uPAR by 3,3′-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. Journal of Cellular Biochemistry 107 516-527.
7. Ahn J, Albanes D, Peters U, Schatzkin A, Lim U, Freedman M, Chatterjee N, Andriole GL, Leitzmann MF & Hayes RB 2007 Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiology, Biomarkers & Prevention 16 2623-2630. (Pubitemid 351196317)
8. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, Haapakoski J, Rautalahti M, Hartman AM, Palmgren J et al. 1995 Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. American Journal of Clinical Nutrition 62 1427S-1430S.
9. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P & Hemmings BA 1996 Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO Journal 15 6541-6551. (Pubitemid 26413787)
10. American Cancer Society 2009 Cancer Facts & Figures 2009. Atlanta: American Cancer Society Inc.
11. Amin AR, Kucuk O, Khuri FR & Shin DM 2009 Perspectives for cancer prevention with natural compounds. Journal of Clinical Oncology 27 2712-2725.
12. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, Breed S, Somerville M & Rittmaster R 2004a Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. Journal of Urology 172 1314-1317.
13. Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M & Rittmaster RS 2004b Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64 537-541.
14. Angers S & Moon RT 2009 Proximal events in Wnt signal transduction. Nature Reviews. Molecular Cell Biology 10 468-477.
15. Antón Aparicio LM, Garcia CR, Cassinello EJ, Valladares AM, Reboredo LM, Diaz PS & Aparicio GG 2007 Prostate cancer and Hedgehog signalling pathway. Clinical & Translational Oncology 9 420-428.
16. Azzi A, Gysin R, Kempna P, Munteanu A, Negis Y, Villacorta L, Visarius T & Zingg JM 2004 Vitamin E mediates cell signaling and regulation of gene expression. Annals of the New York Academy of Sciences 1031 86-95. (Pubitemid 40361745)
17. Banerjee M, Tripathi LM, Srivastava VM, Puri A & Shukla R 2003 Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacology and Immunotoxicology 25 213-224. (Pubitemid 36597418)
18. Banks R, Speakman JR & Selman C 2010 Vitamin E supplementation and mammalian lifespan. Molecular Nutrition & Food Research 54 719-725.
19. Barker N & Clevers H 2006 Mining the Wnt pathway for cancer therapeutics. Nature Reviews. Drug Discovery 5 997-1014. (Pubitemid 44835127)
20. Behrens J 2000 Control of beta-catenin signaling in tumor development. Annals of the New York Academy of Sciences 910 21-33.
21. Benabadji SH, Wen R, Zheng JB, Dong XC & Yuan SG 2004 Anticarcinogenic and antioxidant activity of diindolylmethane derivatives. Acta Pharmacologica Sinica 25 666-671. (Pubitemid 38620693)
22. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G & Corti A 2006 Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Research 66 1234-1240. (Pubitemid 43165995)
23. Bharti AC & Aggarwal BB 2002 Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochemical Pharmacology 64 883-888. (Pubitemid 35238030)
24. Bharti AC, Donato N, Singh S & Aggarwal BB 2003 Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101 1053-1062. (Pubitemid 36139379)
25. Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S & Sarkar FH 2006 Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Research 66 10064-10072. (Pubitemid 44672060)
26. Biancolella M, Valentini A, Minella D, Vecchione L, D'Amico F, Chillemi G, Gravina P, Bueno S, Prosperini G, Desideri A et al. 2007 Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Investigational New Drugs 25 491-497.
27. Bin HB, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, Saleem M, Din M, Setaluri V & Mukhtar H 2009 Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clinical Cancer Research 15 452-459.
28. Biswas DK, Dai SC, Cruz A, Weiser B, Graner E & Pardee AB 2001 The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. PNAS 98 10386-10391.
29. Bracarda S, de CO, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de BF & Bartsch G 2005 Cancer of the prostate. Critical Reviews in Oncology/Hematology 56 379-396.
30. Brausi M, Rizzi F & Bettuzzi S 2008 Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. European Urology 54 472-473.
31. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J & Greenberg ME 1999 Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 857-868. (Pubitemid 29165088)
32. Bureyko T, Hurdle H, Metcalfe JB, Clandinin MT & Mazurak VC 2009 Reduced growth and integrin expression of prostate cells cultured with lycopene, vitamin E and fish oil in vitro. British Journal of Nutrition 101 990-997.
33. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S & Reed JC 1998 Regulation of cell death protease caspase-9 by phosphorylation. Science 282 1318-1321. (Pubitemid 28524494)
34. Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, van BR, Ashton D & Bowen PE 2001 Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. Journal of the National Cancer Institute 93 1872-1879. (Pubitemid 34048654)
35. Chen PC, Wheeler DS, Malhotra V, Odoms K, Denenberg AG & Wong HR 2002 A green tea-derived polyphenol, epigallocatechin-3-gallate, inhibits IkappaB kinase activation and IL-8 gene expression in respiratory epithelium. Inflammation 26 233-241. (Pubitemid 34971887)
36. Chen G, Geng J & Zhang YF 2005 Mechanism of inhibiting the proliferation of prostate cancer by finasteride: a study using cDNA microarray. Zhonghua Yi Xue Za Zhi 85 1489-1492.
37. Chesire DR, Ewing CM, Gage WR & Isaacs WB 2002 In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21 2679-2694.
38. Christensen MJ, Nartey ET, Hada AL, Legg RL & Barzee BR 2007 High selenium reduces NF-kappaB-regulated gene expression in uninduced human prostate cancer cells. Nutrition and Cancer 58 197-204. (Pubitemid 47328771)
39. Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG & Gann PH 2007 Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute 99 1366-1374.
40. Crawford ED, Andriole GL, Marberger M & Rittmaster RS 2010 Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology 75 502-509.
41. Cronauer MV, Schulz WA, Ackermann R & Burchardt M 2005 Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. International Journal of Oncology 26 1033-1040.
42. Dihlmann S & von Knebel DM 2005 Wnt/beta-cateninpathway as a molecular target for future anti-cancer therapeutics. International Journal of Cancer 113 515-524. (Pubitemid 40038726)
43. Dong Y, Zhang H, Hawthorn L, Ganther HE & Ip C 2003 Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Research 63 52-59. (Pubitemid 36070419)
44. Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P, Koscuiszka M, Anand A, Cordon-Cardo C, Costa J & Scher HI 2010 Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU International 105 462-467.
45. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR & Clark LC 2003 Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International 91 608-612.
46. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D & Freeman MR 1999 Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54 523-527.
47. Duvoix A, Morceau F, Delhalle S, Schmitz M, Schnekenburger M, Galteau MM, Dicato M & Diederich M 2003 Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. Biochemical Pharmacology 66 1475-1483.
48. Fares F, Azzam N, Appel B, Fares B & Stein A 2009 The potential efficacy of 3,30-diindolylmethane in prevention of prostate cancer development. European Journal of Cancer Prevention 19 199-203.
49. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH & Stampfer MJ 1999 Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Research 59 1225-1230.
50. Garikapaty VP, Ashok BT, Tadi K, Mittelman A & Tiwari RK 2006 3,3′-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochemical and Biophysical Research Communications 340 718-725. (Pubitemid 43021805)
51. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB & Holick MF 2006 The role of vitamin D in cancer prevention. American Journal of Public Health 96 252-261.
52. Gianduzzo TR, Holmes EG, Tinggi U, Shahin M, Mactaggart P & Nicol D 2003 Prostatic and peripheral blood selenium levels after oral supplementation. Journal of Urology 170 870-873. (Pubitemid 36999579)
53. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ & Willett WC 2002 A prospective study of tomato products, lycopene, and prostate cancer risk. Journal of the National Cancer Institute 94 391-398. (Pubitemid 34257483)
54. Goodman GE, Schaffer S, Omenn GS, Chen C & King I 2003 The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiology, Biomarkers & Prevention 12 518-526. (Pubitemid 36713646)
55. Gupta S, Ahmad N, Nieminen AL & Mukhtar H 2000 Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocate-chin- 3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicology and Applied Pharmacology 164 82-90. (Pubitemid 30198547)
56. Gupta D, Lammersfeld CA, Trukova K & Lis CG 2009 Vitamin D and prostate cancer risk: a review of the epidemiological literature. Prostate Cancer and Prostatic Diseases 12 215-226.
57. Haefner B 2002 NF-kappa B: arresting a major culprit in cancer. Drug Discovery Today 7 653-663. (Pubitemid 34761898)
58. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y & Hampl JS 1998 Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. Journal of the National Cancer Institute 90 1637-1647. (Pubitemid 28523438)
59. Heinlein CA & Chang C 2002 Androgen receptor (AR) coregulators: an overview. Endocrine Reviews 23 175-200.
60. Heinlein CA & Chang C 2004 Androgen receptor in prostate cancer. Endocrine Reviews 25 276-308.
61. Higdon JV, Delage B, Williams DE & Dashwood RH 2007 Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacological Research 55 224-236. (Pubitemid 46518152)
62. Huang S, Pettaway CA, Uehara H, Bucana CD & Fidler IJ 2001 Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 4188-4197. (Pubitemid 32762193)
63. Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC & Bergan RC 2005 Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Research 65 3470-3478. (Pubitemid 40524634)
64. Huang CS, Fan YE, Lin CY & Hu ML 2007 Lycopene inhibits matrix metalloproteinase-9 expression and downregulates the binding activity of nuclear factor-kappa B and stimulatory protein-1. Journal of Nutritional Biochemistry 18 449-456.
65. Ismail HA, Lessard L, Mes-Masson AM & Saad F 2004 Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate 58 308-313. (Pubitemid 38168929)
66. Jacobsen BK, Knutsen SF & Fraser GE 1998 Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States) Cancer Causes & Control 9 553-557.
67. Jemal A, Siegel R, Ward E, Hao Y, Xu J & Thun MJ 2009 Cancer statistics, 2009. CA: A Cancer Journal for Clinicians 59 225-249.
68. Jian L, Lee AH & Binns CW 2007 Tea and lycopene protect against prostate cancer. Asia Pacific Journal of Clinical Nutrition 16 (Supplement 1) 453-457. (Pubitemid 46524644)
69. Johnson JJ, Bailey HH & Mukhtar H 2010 Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine 17 3-13.
70. Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, Heyden NL & Vaughan ED Jr 2009 PCPT: evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology 73 935-939.
71. Karin M, Cao Y, Greten FR & Li ZW 2002 NF-kappaB in cancer: from innocent bystander to major culprit. Nature Reviews. Cancer 2 301-310. (Pubitemid 37328783)
72. Khan N & Mukhtar H 2008 Multitargeted therapy of cancer by green tea polyphenols. Cancer Letters 269 269-280.
73. Khan N, Adhami VM & Mukhtar H 2009 Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutrition and Cancer 61 836-841.
74. Kim L, Rao AV & Rao LG 2002 Effect of lycopene on prostate LNCaP cancer cells in culture. Journal of Medicinal Food 5 181-187. (Pubitemid 36331630)
75. Kim GY, Kim JH, Ahn SC, Lee HJ, Moon DO, Lee CM & Park YM 2004 Lycopene suppresses the lipopolysaccharide- induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and nuclear factor-kappaB. Immunology 113 203-211. (Pubitemid 39312448)
76. Kim J, Zhang X, Rieger-Christ KM, Summerhayes IC, Wazer DE, Paulson KE & Yee AS 2006 Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. Journal of Biological Chemistry 281 10865-10875.
77. Klein EA 2004 Selenium: epidemiology and basic science. Journal of Urology 171 S50-S53.
78. Klein EA, Lippman SM, Thompson IM, Goodman PJ, Albanes D, Taylor PR & Coltman C 2003 The selenium and vitamin E cancer prevention trial. World Journal of Urology 21 21-27. (Pubitemid 44175292)
79. Kong D, Li Y, Wang Z, Banerjee S & Sarkar FH 2007 Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Research 67 3310-3319.
80. Kong D, Banerjee S, Huang W, Li Y, Wang Z, Kim HR & Sarkar FH 2008 Mammalian target of rapamycin repression by 3,3′-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Research 68 1927-1934.
81. Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, Li YW, Banerjee M, Grignon D, Bertram JS et al. 2001 Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiology, Biomarkers & Prevention 10 861-868.
82. Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, Khachik F, Banerjee M, Bertram JS & Wood DP Jr 2002 Effects of lycopene supplementation in patients with localized prostate cancer. Experimental Biology and Medicine 227 881-885. (Pubitemid 35340342)
83. Kupelian P, Katcher J, Levin H, Zippe C & Klein E 1996 Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48 249-260. (Pubitemid 26279618)
84. Kurahashi N, Sasazuki S, Iwasaki M, Inoue M & Tsugane S 2008 Green tea consumption and prostate cancer risk in Japanese men: a prospective study. American Journal of Epidemiology 167 71-77.
85. Le HT, Schaldach CM, Firestone GL & Bjeldanes LF 2003 Plant-derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. Journal of Biological Chemistry 278 21136-21145. (Pubitemid 36806427)
86. Lee HJ & Chang C 2003 Recent advances in androgen receptor action. Cellular and Molecular Life Sciences 60 1613-1622. (Pubitemid 37041360)
87. Lee MM, Wang RT, Hsing AW, Gu FL, Wang T & Spitz M 1998 Case - control study of diet and prostate cancer in China. Cancer Causes & Control 9 545-552. (Pubitemid 29046126)
88. Legg RL, Tolman JR, Lovinger CT, Lephart ED, Setchell KD & Christensen MJ 2008 Diets high in selenium and isoflavones decrease androgen-regulated gene expression in healthy rat dorsolateral prostate. Reproductive Biology and Endocrinology 6 57.
89. Li J & Kim J 2009 Molecular profiles of finasteride effects on prostate carcinogenesis. Cancer Prevention Research 2 518-524.
90. Li Y & Sarkar FH 2002a Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clinical Cancer Research 8 2369-2377. (Pubitemid 34753612)
91. Li Y & Sarkar FH 2002b Gene expression profiles of genistein-treated PC3 prostate cancer cells. Journal of Nutrition 132 3623-3631. (Pubitemid 35435038)
92. Li Q & Verma IM 2002 NF-kappaB regulation in the immune system. Nature Reviews. Immunology 2 725-734.
93. Li Y, Li X & Sarkar FH 2003 Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. Journal of Nutrition 133 1011-1019. (Pubitemid 36407118)
94. Li Y, Wang Z, Kong D, Murthy S, Dou QP, Sheng S, Reddy GP & Sarkar FH 2007 Regulation of FOXO3a/beta-catenin/ GSK-3beta signaling by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. Journal of Biological Chemistry 282 21542-21550. (Pubitemid 47099972)
95. Li Y, Wang Z, Kong D, Li R, Sarkar SH & Sarkar FH 2008 Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. Journal of Biological Chemistry 283 27707-27716.
96. Limpens J, van Weerden WM, Kramer K, Pallapies D, Obermuller-Jevic UC & Schroder FH 2004 Re: prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. Journal of the National Cancer Institute 96 554-555.
97. Lin A & Karin M 2003 NF-kappaB in cancer: a marked target. Seminars in Cancer Biology 13 107-114.
98. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA et al. 2009 Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the American Medical Association 301 39-51.
99. Liu X, Allen JD, Arnold JT & Blackman MR 2008 Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells. Carcinogenesis 29 816-823. (Pubitemid 351494170)
100. Liu P, Cheng H, Roberts TM & Zhao JJ 2009 Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews. Drug Discovery 8 627-644.
101. Lu QY, Hung JC, Heber D, Go VL, Reuter VE, Cordon- Cardo C, Scher HI, Marshall JR & Zhang ZF 2001 Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 10 749-756. (Pubitemid 32695154)
102. Maillard I & Pear WS 2003 Notch and cancer: best to avoid the ups and downs. Cancer Cell 3 203-205. (Pubitemid 37443875)
103. Marberger M 2006 Drug insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia. Nature Clinical Practice. Urology 3 495-503. (Pubitemid 44377540)
104. McCormick DL, Rao KV, Johnson WD, Bosland MC, Lubet RA & Steele VE 2010 Null activity of selenium and vitamin E as cancer chemopreventive agents in the rat prostate. Cancer Prevention Research 3 381-392.
105. Medina V, Calvo MB, Díaz-Prado S & Espada J 2009 Hedgehog signalling as a target in cancer stem cells. Clinical & Translational Oncology 11 199-207.
106. Meyer MB, Goetsch PD & Pike JW 2010 A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1{alpha},25-dihydroxyvitamin D3. Journal of Biological Chemistry 285 15599-15610.
107. Miele L, Miao H & Nickoloff BJ 2006 NOTCH signaling as a novel cancer therapeutic target. Current Cancer Drug Targets 6 313-323. (Pubitemid 43961866)
108. Miquel J, Bernd A, Sempere JM, az-Alperi J & Ramirez A 2002 The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Archives of Gerontology and Geriatrics 34 37-46.
109. Montgomery JS, Price DK & Figg WD 2001 The androgen receptor gene and its influence on the development and progression of prostate cancer. Journal of Pathology 195 138-146. (Pubitemid 32899021)
110. Morgan TM, Koreckij TD & Corey E 2009 Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Current Cancer Drug Targets 9 237-249.
111. Musquera M, Fleshner NE, Finelli A & Zlotta AR 2008 The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Review of Anticancer Therapy 8 1073-1079.
112. Nachshon-Kedmi M, Fares FA & Yannai S 2004 Therapeutic activity of 3,3′-diindolylmethane on prostate cancer in an in vivo model. Prostate 61 153-160. (Pubitemid 39244702)
113. Nahum A, Hirsch K, Danilenko M, Watts CK, Prall OW, Levy J & Sharoni Y 2001 Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene 20 3428-3436. (Pubitemid 32588991)
114. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H & Sawyers CL 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. PNAS 98 10314-10319. (Pubitemid 32803017)
115. Nho CW & Jeffery E 2004 Crambene, a bioactive nitrile derived from glucosinolate hydrolysis, acts via the antioxidant response element to upregulate quinone reductase alone or synergistically with indole-3-carbinol. Toxicology and Applied Pharmacology 198 40-48. (Pubitemid 38789127)
116. Ohtsu H, Xiao Z, Ishida J, Nagai M, Wang HK, Itokawa H, Su CY, Shih C, Chiang T, Chang E et al. 2002 Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. Journal of Medicinal Chemistry 45 5037-5042.
117. Orlowski RZ & Baldwin AS Jr 2002 NF-kappaB as a therapeutic target in cancer. Trends in Molecular Medicine 8 385-389.
118. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM & Donner DB 1999 NF-kappaB activation by tumour necrosis factor requires the Akt serine - threonine kinase. Nature 401 82-85.
119. Palozza P, Sheriff A, Serini S, Boninsegna A, Maggiano N, Ranelletti FO, Calviello G & Cittadini A 2005 Lycopene induces apoptosis in immortalized fibroblasts exposed to tobacco smoke condensate through arresting cell cycle and down-regulating cyclin D1, pAKT and pBad. Apoptosis 10 1445-1456. (Pubitemid 43117688)
120. Peifer M & Polakis P 2000 Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 287 1606-1609. (Pubitemid 30127755)
121. Pike JW, Meyer MB, Martowicz ML, Bishop KA, Lee SM, Nerenz RD & Goetsch PD 2010 Emerging regulatory paradigms for control of gene expression by 1,25-dihydroxyvitamin D(3). Journal of Steroid Biochemistry and Molecular Biology.
122. Pinski J, Wang Q, Quek ML, Cole A, Cooc J, Danenberg K & Danenberg PV 2006 Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 66 1136-1143. (Pubitemid 44175336)
123. Qin J, Xie LP, Zheng XY, Wang YB, Bai Y, Shen HF, Li LC & Dahiya R 2007 A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Biochemical and Biophysical Research Communications 354 852-857. (Pubitemid 46216211)
124. Ren F, Zhang S, Mitchell SH, Butler R & Young CY 2000 Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 19 1924-1932. (Pubitemid 30219035)
125. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM & Egger M 2004 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 1346-1353.
126. Reya T & Clevers H 2005 Wnt signalling in stem cells and cancer. Nature 434 843-850. (Pubitemid 40558990)
127. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B &Miele L 2008 Rational targeting of Notch signaling in cancer. Oncogene 27 5124-5131.
128. Rochette-Egly C 2003 Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cellular Signalling 15 355-366. (Pubitemid 36254908)
129. Romashkova JA & Makarov SS 1999 NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401 86-90.
130. Ryu MJ, Cho M, Song JY, Yun YS, Choi IW, Kim DE, Park BS & Oh S 2008 Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochemical and Biophysical Research Communications 377 1304-1308.
131. Saez C, Gonzalez-Baena AC, Japon MA, Giraldez J, Segura DI, Miranda G, Rodriguez-Vallejo JM, Gonzalez-Esteban J & Torrubia F 1998 Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-beta receptor expression. Prostate 37 84-90. (Pubitemid 28440134)
132. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM et al. 2004 JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Research 64 6854-6857. (Pubitemid 39330990)
133. Sarkar FH, Li Y, Wang Z & Kong D 2008 NF-kappaB signaling pathway and its therapeutic implications in human diseases. International Reviews of Immunology 27 293-319.
134. Sarker D, Reid AH, Yap TA & de Bono JS 2009 Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clinical Cancer Research 15 4799-4805.
135. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH & Sullivan LD 1996 Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. Journal of Steroid Biochemistry and Molecular Biology 58 139-146. (Pubitemid 26284510)
136. Sawaya ME, Blume-Peytavi U, Mullins DL, Nusbaum BP, Whiting D, Nicholson DW, Lotocki G & Keane RW 2002 Effects of finasteride on apoptosis and regulation of the human hair cycle. Journal of Cutaneous Medicine and Surgery 6 1-9. (Pubitemid 34279786)
137. Schmidt LJ, Murillo H & Tindall DJ 2004 Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride. Journal of Andrology 25 944-953. (Pubitemid 39425600)
138. Schmidt LJ, Regan KM, Anderson SK, Sun Z, Ballman KV & Tindall DJ 2009 Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. Prostate 69 1730-1743.
139. Shah YM, Kaul A, Dong Y, Ip C & Rowan BG 2005 Attenuation of estrogen receptor alpha (ERalpha) signaling by selenium in breast cancer cells via downregulation of ERalpha gene expression. Breast Cancer Research and Treatment 92 239-250. (Pubitemid 41279634)
140. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM & Slawin KM 2004 Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. Journal of Clinical Oncology 22 1655-1663.
141. Shou J, Ross S, Koeppen H, de Sauvage FJ & Gao WQ 2001 Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Research 61 7291-7297. (Pubitemid 32951774)
142. Shukla S, MacLennan GT, Marengo SR, Resnick MI & Gupta S 2005 Constitutive activation of PI3K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 64 224-239. (Pubitemid 40980864)
143. Slusarz A, Shenouda NS, Sakla MS, Drenkhahn SK, Narula AS, MacDonald RS, Besch-Williford CL & Lubahn DB 2010 Common botanical compounds inhibit the Hedgehog signaling pathway in prostate cancer. Cancer Research 70 3382-3390.
144. de Souza PL, Russell PJ & Kearsley J 2009 Role of the Akt pathway in prostate cancer. Current Cancer Drug Targets 9 163-175.
145. Storz P & Toker A 2003 NF-kappaB signaling - an alternate pathway for oxidative stress - responses. Cell Cycle 2 9-10.
146. Su Y & Simmen RC 2009 Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates beta-catenin signaling in mammary epithelial cells. Carcinogenesis 30 331-339.
147. Su Y, Simmen FA, Xiao R & Simmen RC 2007 Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. Physiological Genomics 30 8-16. (Pubitemid 47173284)
148. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C & Rabson AB 2002 Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 52 183-200. (Pubitemid 34791221)
149. Syed DN, Khan N, Afaq F & Mukhtar H 2007 Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiology, Biomarkers & Prevention 16 2193-2203. (Pubitemid 351196348)
150. Syed DN, Suh Y, Afaq F & Mukhtar H 2008 Dietary agents for chemoprevention of prostate cancer. Cancer Letters 265 167-176.
151. Taipale J & Beachy PA 2001 The Hedgehog and Wnt signalling pathways in cancer. Nature 411 349-354. (Pubitemid 32467044)
152. Tang FY, Nguyen N & Meydani M 2003 Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. International Journal of Cancer 106 871-878. (Pubitemid 37071665)
153. Tang FY, Shih CJ, Cheng LH, Ho HJ & Chen HJ 2008 Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway. Molecular Nutrition & Food Research 52 646-654.
154. Thompson TA & Wilding G 2003 Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. Molecular Cancer Therapeutics 2 797-803.
155. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM et al. 2003 The influence of finasteride on the development of prostate cancer. New England Journal of Medicine 349 215-224.
156. Varjosalo M & Taipale J 2008 Hedgehog: functions and mechanisms. Genes and Development 22 2454-2472.
157. Verras M & Sun Z 2006 Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Letters 237 22-32.
158. Vezina CM & Bushman AW 2007 Hedgehog signaling in prostate growth and benign prostate hyperplasia. Current Urology Reports 8 275-280. (Pubitemid 47168308)
159. Vunta H, Belda BJ, Arner RJ, Channa RC, Vanden Heuvel JP & Sandeep PK 2008 Selenium attenuates pro-inflammatory gene expression in macrophages. Molecular Nutrition & Food Research 52 1316-1323.
160. Wang Z, Zhang Y, Banerjee S, Li Y & Sarkar FH 2006a Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. International Journal of Cancer 118 1930-1936.
161. Wang Z, Zhang Y, Banerjee S, Li Y & Sarkar FH 2006b Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106 2503-2513. (Pubitemid 43787677)
162. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, Hay N & Sarkar FH 2010 Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. Journal of Cellular Biochemistry 109 726-736.
163. Waters DJ, Shen S, Cooley DM, Bostwick DG, Qian J, Combs GF Jr, Glickman LT, Oteham C, Schlittler D & Morris JS 2003 Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. Journal of the National Cancer Institute 95 237-241. (Pubitemid 36240637)
164. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH & Hung MC 2000 HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Research 60 6841-6845. (Pubitemid 32059149)
165. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW et al. 1995 Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. Journal of the National Cancer Institute 87 652-661.
166. Yamamoto Y & Gaynor RB 2001 Role of the NF-kappaB pathway in the pathogenesis of human disease states. Current Molecular Medicine 1 287-296. (Pubitemid 33773312)
167. Yang F, Oz HS, Barve S, de Villiers WJ, McClain CJ & Varilek GW 2001 The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Molecular Pharmacology 60 528-533. (Pubitemid 32781560)
168. Yang L, Xie G, Fan Q & Xie J 2010 Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 29 469-481.
169. Yu S, Shen G, Khor TO, Kim JH & Kong AN 2008 Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase- dependent mechanism. Molecular Cancer Therapeutics 7 2609-2620.
170. Zardawi SJ, O'Toole SA, Sutherland RL & Musgrove EA 2009 Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histology and Histopathology 24 385-398.
171. Zeng H & Botnen JH 2007 Selenium is critical for cancer-signaling gene expression but not cell proliferation in human colon Caco-2 cells. Biofactors 31 155-164. (Pubitemid 352789883)
172. Zhao H, Whitfield ML, Xu T, Botstein D & Brooks JD 2004 Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Molecular Biology of the Cell 15 506-519. (Pubitemid 38146469)